François Lifermann

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)

Pierre Charles, Benjamin Terrier, Élodie Perrodeau et al. · Annals of the Rheumatic Diseases · 2018 · 336 citations

Life Sciences, Immunology, Pharmacotherapy +15

Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With <i>BRAF^V600E</i>-Mutated Erdheim-Chester Disease

Julien Haroche, Fleur Cohen‐Aubart, Jean‐François Emile et al. · Journal of Clinical Oncology · 2014 · 287 citations

Medicine, Oncology, Pharmacotherapy +13

Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation

B. Hervier, Julien Haroche, Laurent Arnaud et al. · Blood · 2014 · 255 citations

Medicine, Genetics, Molecular Genetics +12

Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Pierre Charles, Élodie Perrodeau, M. Samson et al. · Annals of Internal Medicine · 2020 · 193 citations

Medicine, Clinical Sciences, Pharmacotherapy +17

Usefulness of 2‐[¹⁸F]‐fluoro‐2‐deoxy‐<scp>d</scp>‐glucose–Positron Emission Tomography/Computed Tomography for Staging and Evaluation of Treatment Response in IgG4‐Related Disease: A Retrospective Multicenter Study

Mikaël Ebbo, A. Grados, Éric Guedj et al. · Arthritis Care & Research · 2013 · 189 citations

Medicine, Oncology, Radiology +17